Skip to main navigation Skip to search Skip to main content

PREGO (presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012

  • Petros Perros*
  • , Milo͉ Zarkovi
  • , Claudio Azzolini
  • , Göksun Ayvaz
  • , Lelio Baldeschi
  • , Luigi Bartalena
  • , Antonella Boschi
  • , Claire Bournaud
  • , Thomas Heiberg Brix
  • , Danila Covelli
  • , Slavica Iri
  • , Chantal Daumerie
  • , Anja Eckstein
  • , Nicole Fichter
  • , Dagmar Führer
  • , Laszlo Hegedüs
  • , George J. Kahaly
  • , Onur Konuk
  • , Jürg Lareida
  • , John Lazarus
  • Marenza Leo, Lemonia Mathiopoulou, Francesca Menconi, Daniel Morris, Onyebuchi Okosieme, Jaques Orgiazzi, Susanne Pitz, Mario Salvi, Cristina Vardanian-Vartin, Wilmar Wiersinga, Martine Bernard, Lucy Clarke, Nicola Currò, Colin Dayan, Jane Dickinson, Miroslav Knezevi, Carol Lane, Claudio Marcocci, Michele Marinò, Lars Möller, Marco Nardi, Christopher Neoh, Simon Pearce, George Von Arx, Fosun Balo Törüner
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background/aims The epidemiology of Graves' orbitopathy (GO) may be changing. The aim of the study was to identify trends in presentation of GO to tertiary centres and initial management over time. Methods Prospective observational study of European Group On Graves' Orbitopathy (EUGOGO) centres. All new referrals with a diagnosis of GO over a 4-month period in 2012 were included. Clinical and demographic characteristics, referral timelines and initial decisions about management were recorded. The data were compared with a similar EUGOGO survey performed in 2000. Results The demographic characteristics of 269 patients studied in 2012 were similar to those collected in the year 2000, including smoking rates (40.0% vs 40.2%). Mild (60.5% vs 41.2%, p<0.01) and inactive GO (63.2% vs 39.9%, p<0.01) were more prevalent in 2012. The times from diagnosis of thyroid disease to being seen in EUGOGO centres (6 vs 16 months) and from first symptoms of GO (9 vs 16 months) or from diagnosis of GO (6 vs 12 months) to first consultation in EUGOGO centres were shorter in 2012 ( p<0.01). The initial management plans for GO were no different except surgical treatments for patients with mild inactive disease were more frequently offered in the 2012 cohort than in 2000 (27.3% vs 17%, p<0.05), and selenium supplements were offered only in the 2012 cohort (21.2% vs 0%, p<0.01). Conclusions These findings suggest that the clinical manifestations of patients with GO may be changing over time in Europe.

Original languageEnglish
Pages (from-to)1531-1535
Number of pages5
JournalBritish Journal of Ophthalmology
Volume99
Issue number11
DOIs
Publication statusPublished - Nov 2015

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Fingerprint

Dive into the research topics of 'PREGO (presentation of Graves' orbitopathy) study: Changes in referral patterns to European Group on Graves' Orbitopathy (EUGOGO) centres over the period from 2000 to 2012'. Together they form a unique fingerprint.

Cite this